Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (177Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.
Trial registration: ClinicalTrials.gov NCT03511664 NCT03872778.
Keywords: (177)Lu-DOTATATE; PRRT; individualised; neuroendocrine tumours; personalised; radionuclide therapy.
Copyright © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.